Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAON CL-10 vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving diuretics or other drugs that deplete potassium
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Terminal elimination half-life is approximately 3-5 hours in healthy adults, reflecting rapid equilibration with the total body potassium pool. Clinically, the half-life is not directly applicable due to extensive intracellular distribution; steady-state is achieved within 24-48 hours.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is primarily excreted unchanged by the kidneys; metabolism is not significant.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Primarily renal elimination (>90% as unchanged drug); minor biliary/fecal excretion (<5%). Excretion is via glomerular filtration and tubular reabsorption; potassium excretion is influenced by aldosterone and acid-base status.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Potassium is not significantly protein-bound; <5% bound to plasma proteins.
70–80% (primarily to albumin).
Approximately 0.5 L/kg, representing distribution primarily into intracellular fluid (98% of total body potassium is intracellular). Clinical meaning: Low Vd indicates limited distribution to extracellular space; high intracellular uptake requires careful dosing to avoid hyperkalemia.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Oral: >90% absorbed via passive diffusion along the gastrointestinal tract. Intravenous: 100% bioavailability.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Oral: 1-3 m Eq/kg/day in divided doses, maximum 3 m Eq/kg/day; not recommended for children <1 year.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Start at lowest dose (10 m Eq twice daily); monitor renal function and potassium levels; avoid doses exceeding 40 m Eq/day.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Warning: Potassium chloride can cause hyperkalemia and cardiac arrest if given too rapidly or in excessive doses. Avoid in patients with severe renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics.
No FDA black box warning is present for HEMICLOR.
Monitor serum potassium levels and renal function; avoid high doses or rapid infusion; use with caution in patients with cardiac disease or receiving digitalis; gastrointestinal irritation may occur with oral preparations.
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Severe renal impairment (e.g., anuria, oliguria), untreated Addison's disease, hyperkalemia from any cause, acute dehydration, heat cramps, concurrent use of potassium-sparing diuretics (e.g., amiloride, spironolactone), hypersensitivity to potassium chloride.
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid salt substitutes and low-sodium products that contain potassium chloride. No specific food restrictions beyond ensuring adequate water intake with each dose to prevent esophageal or gastric irritation.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been reported. Hypokalemia itself may pose maternal and fetal risks, but the drug does not have intrinsic teratogenic potential.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium chloride is a normal constituent of breast milk. M/P ratio not applicable as potassium is present endogenously. Supplementation to correct maternal hypokalemia is considered safe during breastfeeding, as potassium levels in milk are tightly regulated and maternal supplementation does not significantly alter infant potassium levels.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
No dose adjustment required for pregnancy. Maternal potassium requirements may increase slightly due to increased plasma volume and renal blood flow, but hypokalemia should be corrected per standard guidelines. Monitor serum potassium to avoid hyperkalemia.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Kaon CL-10 is a solid oral dosage form of potassium chloride (KCl) 10 m Eq. Do not split or crush tablets; they must be swallowed whole with a full glass of water to reduce GI irritation. Monitor serum potassium, renal function, and ECG. Use with caution in patients with impaired renal function or those on ACE inhibitors, ARBs, or potassium-sparing diuretics. Rapid IV correction is reserved for severe hypokalemia with ECG changes.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Take this medication with food and a full glass of water to prevent stomach upset.,Do not crush, chew, or split the tablet; swallow it whole.,Missing a dose: take it as soon as you remember unless almost time for the next dose; do not double up.,Report symptoms of high potassium: muscle weakness, tiredness, numbness/tingling, irregular heartbeat, or confusion.,Do not use salt substitutes or potassium-containing supplements unless directed by your doctor.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAON CL-10 vs HEMICLOR, answered by our medical review team.
KAON CL-10 is a Electrolyte Supplement (Potassium) that works by Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAON CL-10 and HEMICLOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAON CL-10 is: Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAON CL-10 and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAON CL-10 is classified as Category C. Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been report. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.